Publication Date
5-1-2024
Journal
Kidney360
DOI
10.34067/KID.0000000000000387
PMID
38323855
PMCID
PMC11146652
PubMedCentral® Posted Date
2-7-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Female, Humans, Male, Middle Aged, Hyperphosphatemia, Isoquinolines, Renal Dialysis, Sulfonamides, Treatment Outcome, hyperphosphatemia, tenapanor, CKD, maintenance dialysis, phosphate binders
Abstract
KEY POINTS: Tenapanor, a first-in-class local inhibitor of sodium/hydrogen exchanger isoform 3, acts as a phosphate absorption inhibitor by decreasing paracellular phosphate absorption. Tenapanor alone or with phosphate binders achieved
BACKGROUND: OPTIMIZE was a randomized, open-label study evaluating different tenapanor initiation methods. OPTIMIZE evaluated tenapanor alone and in combination with phosphate binders (PBs) to achieve target serum phosphate (P) ≤5.5 mg/dl.
METHODS: Patients with inadequately controlled P receiving maintenance dialysis from 42 US locations who were taking PBs with baseline
RESULTS: By part A end point, 34.4% (
CONCLUSIONS: Tenapanor as monotherapy or in combination with PBs effectively lowered P toward the target range in patients who were PB-naive or who were not at goal despite PB use.
CLINICAL TRIAL REGISTRATION NUMBER: NCT04549597.
Graphical Abstract
Included in
Diseases Commons, Internal Medicine Commons, Medical Sciences Commons, Nephrology Commons